Zolmitriptan, a 5-HT(1B/1D) receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study

European Journal of Neurology

Volumn 5, Issue 6, 1998, Pages 535-543

  Dahlöf, Carl ^a   Diener, Hans Christoph ^b   Goadsby, Peter J ^c   Massiou, Hélène ^d   Olesen, Jes ^e   Schoenen, Jean ^f,j   Wilkinson, Marcia ^g   Sweet, Ruth M ^h   Klein, Ken B ⁱ  

^a Gothenburg Migraine Clinic   (Sweden)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g City of London Migraine Clinic   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ Intl Drug Development Consulting   (United States)

^j Centre Hospitalier Regional de La Citadelle   (Belgium)

more..

Author keywords

5HT(1B 1D) receptor agonist; Dose range finding; Migraine; Zolmitriptan

Indexed keywords

ANTIMIGRAINE AGENT; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; VERTIGO;

EID: 0031765420     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1998.560535.x     Document Type: Article

References (26)

1. Dechant KL, Clissold SP (1992). Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of migraine and cluster headache. Drugs 43:776-798.
2. Diener HC (1994). A review of current treatments for migraine. European Neurology 34 (Suppl. 2):18-25.
3. Diener HC, Klein KB (1996). The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Functional Neurology 11:152, abstract 24b and poster presented at the 3rd European Headache Conference 5-8 June, Sardinia.
4. Dixon R, Warrander A (1997). The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17 (Suppl. 18):15-20.
5. 1B/1D agonist. Cephalalgia 17 (Suppl. 18):41-52.
6. Goadsby PJ, Edvinsson L (1994). Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90. Headache 34:394-399.
7. 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 67:355-359.
8. Goadsby P, Olesen J (1996). Diagnosis and management of migraine. British Medical Journal 312:1279-1283.
9. Goadsby PJ, Knight YE (1997). Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in the cat. Cephalalgia 17:153-158.
10. Göbel H, Petersen-Braun M, Heinze A (1997). Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Frontiers in Headache Research, Vol. 6, Headache Treatment. Trial Methodology and New Drugs (Eds J Olesen and P Tfelt-Hansen), pp. 93-98 Philadelphia, Lippincott-Raven.
11. Headache Classification Committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8 (Suppl. 7):1-96.
12. Martin G (1997). Pre-clinical pharmacology of zolmitriptan (Zomig™, formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia 17 (Suppl. 18):4-14.
13. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Honey AC, et al. (1997). Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D partial agonist, 311C90 (zolmitriptan). British Journal of Pharmacology 121:157-164.
14. 1D) agonists and other agents in acute migraine. Neurologic Clinics 15:61-83.
15. Osterhaus JT, Gutterman DL, Plachet KA (1992). Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 2:67-76.
16. 1B/1D agonist zolmitriptan (311C90, Zomig™). Cephalalgia 17:849-854.
17. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl N, on behalf of the 017 Clinical Trial Study Group (1997). Optimizing the dose of zolmitriptan ('Zornig', 311C90) in the acute treatment of migraine. Neurology 49:1210-1218.
18. Rasmussen BK (1995). Epidemiology of headache. Cephalalgia 15:45-68.
19. 1B/1D agonist: an overview of efficacy. Cephalalgia 17 (Suppl. 18):28-40.
20. Schoenen J, Klein KB, Sweet RM (1996). The CNS adverse event profiles of 311C90 and sumatriptan appear identical. European Journal of Neurology 3 (Suppl. 5), 153 abs 410 and poster presented at the 2nd Congress of the European Federation of Neurological Sciences, Rome.
21. Simmons VE, Blakeborough P (1994). The safety profile of sumatriptan. Reviews in Contemporary Pharmacotherapy 5:319-328.
22. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992). Prevalence of migraine headache in the United States. Journal of the American Medical Association 267:64-69.
23. Storer RJ, Goadsby PJ (1998). Microiontophoretic application of serotonin (5HT)-1B/1D agonists inhibits trigeminal cell firing in the cat. Brain, (in press).
24. Visser WH, Ferrari MD, Klein KB, Cox RC, Jones D (1996a). An in-patient, placebo-controlled, dose-ranging study of oral zolmitriptan in the acute treatment of migraine. Neurology 46:522-526.
25. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group (1996b). Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Archives of Neurology 53:1132-1137.
26. Zagami AS, for the International 311C90 Long-Term Study Group (1997). 31IC90: Long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 48 (Suppl. 3):S25-28.